reports
Trading by management and close relations of management
Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of Novonesis Group reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please read the full announcement in PDF. Attachment
- ABGSC IT Research
- Herman Caspersen
- Øystein Elton Lodgaard
Novonesis will host an educational conference call on Energy on Decemb...
Novonesis will host an educational conference call on Energy on December 18 Novonesis will host a spotlight educational session on our Energy activities which is part of Planetary Health Biosolutions. We will share insights about the industry, its development, and Novonesis’ integral part of the industry’s value chain. The session will be hosted as a conference call on December 18 at 15:00 CET. To join the live webcast, please click . To register and receive access details for the conference call, please click . Attachment
- Håkon Astrup
Sparebanken Vest (Buy, TP: NOK158.00) - Long-term synergy potential
In this note, we have included the merger with Sparebanken Sør in our estimates (scheduled for 1 May 2025 pending regulatory approval). The banks have guided for annual operating synergies of NOK350m–400m from 2027–2028, as well as combined capital benefits of NOK4.1bn (NOK2.1bn from the new standard method and NOK2bn from SVEG’s IRB models). While we have cut our 2025–2026e EPS by ~5% due to the synergy time lag, we expect the merger to be accretive longer-term. Also seeing generous dividend pr...
- Geir Hiller Holom
PhotoCure (Buy, TP: NOK84.00) - Set to meet 2024 targets
Q3 revenues were NOK120.2m (up 12% YOY) and EBITDA was NOK5m (Q3 2023 NOK3.3m). We still expect the company to meet its financial targets for 2024, and have largely maintained our 2024–2028e EPS. We have removed future potential Asieris milestone payments from our estimates, now viewing this as upside potential to our base case. Following a change of analyst, we have cut our target price to NOK84 (87), but reiterate our BUY as we continue to find the valuation attractive.
Major shareholder announcement
Major shareholder announcement Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments. Per November 11, 2024, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,180,630 shares, corresponding to 4.94% (previously 5.02%) of the total share capital attached to shares. The combined total of share capital attached to shares and share capital through financial instr...
- ABGSC Energy Research
- Åsne Holsen
- Daniel Vårdal Haugland
- Haakon Amundsen
- John Olaisen
- Stian Wibstad
- ABGSC Renewable Energy Research
- Adrian Gilani
- Åsne Holsen
- Daniel Vårdal Haugland
- Haakon Amundsen
- John Olaisen
- Stian Wibstad
ORSTED ORSTED
HEX HEXAGON COMPOSITES ASA
NEL NEL ASA
SSO SCATEC ASA
EOLU B EOLUS VIND AB
FKRFT FJORDKRAFT HOLDING ASA
CADLR CADELER
VOLUE VOLUE AS
A2QKGG HEXAGON PURUS
ZAP ZAPTEC
VWS VESTAS WIND SYSTEMS
EWIND EDDA WIND ASA
TOM TOMRA SYSTEMS ASA
IWS-NO INTEGRATED WIND SOLUTIONS
OX2-SE OX2
- ABGSC Consumer Goods Research
- Benjamin Wahlstedt
- Fredrik Ivarsson
- ABGSC Financials Research
- Fredrik Flørnes Støle
- Jan Erik Gjerland
Sampo: 1 director
A director at Sampo sold 28,593 shares at 303.280DKK and the significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing ...
Q3 update: Novonesis delivers strong Q3 results and now expects full-y...
Q3 update: Novonesis delivers strong Q3 results and now expects full-year organic sales growth at the upper end of 7-8% Following increasing demand in the first nine months of the 2024 financial year, Novonesis delivers 9% organic sales growth with a strong 11% organic sales growth in the third quarter. The strong performance has led Novonesis to now expect full-year organic sales growth to be at the upper end of the 7-8% range, and the adjusted EBITDA margin is confirmed to be between 35.5-36.5%. COPENHAGEN, Denmark – November 7, 2024. Novonesis delivers 9% organic sales growth, in the fir...
Trading statement 9M 2024
Trading statement 9M 2024 Organic pro forma sales growth of 9%, including 11% in the third quarter. Full-year organic sales growth outlook now expected at the upper end of the 7-8% range and the adjusted EBITDA margin confirmed between 35.5-36.5%. Ester Baiget, President & CEO: “We continue to execute strongly across the business. Supportive, broad-based demand coupled with strong innovation and commercial focus drive higher market penetration. Novonesis’ biosolutions are increasingly requested by customers to make their products and processes healthier and more efficient, with less...
- Håkon Astrup
Sampo Oyj (Buy, TP: EUR48.00) - Pricing power remains strong
Helped by strong growth in both Hastings and recently acquired Topdanmark, Sampo reported PTP 11% higher YOY in Q3. Underwriting performance continues to be strong in Hastings and If P&C, where the underlying claims ratio improved 0.3%-points YOY. We have made limited 2025–2026e EPS changes in light of the report. We reiterate our BUY and EUR48 target price.
- Roy Külter
- Steven Boumans
- Thomas Zlowodzki
ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 11/06/2024
Our baseline scenario materialised last night: Donald Trump seems to be on course to win the US presidential election, and the choice of the electorate is unlikely to be challenged. He could end up with a majority in both houses of Congress. US equities will be the first to benefit from this development. In European equities, the biggest winners will be Energy, Media, Metals, Construction & Materials, Financial Services and Insurance. More at risk, however, are the Utilities, Spirits,...
AKE ARKEMA
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
UBSN UBS GROUP AG
PUM PUMA SE
EN BOUYGUES SA
VNA VONOVIA SE
ORSTED ORSTED
FRE FRESENIUS SE & CO. KGAA
NEX NEXANS SA
HEN3 HENKEL AG & CO. KGAA PREF
EDW EDP RENOVAVEIS SA
EVK EVONIK INDUSTRIES AG
INW INFRASTRUTTURE WIRELESS ITALIANE S.P.A.
COLO B COLOPLAST A/S CLASS B
RACE FERRARI NV
AD KONINKLIJKE AHOLD DELHAIZE N.V.
AZN ASTRAZENECA PLC
VOD VODAFONE GROUP PLC
SHL SIEMENS HEALTHINEERS AG
NEOEN NEOEN S.A.
VWS VESTAS WIND SYSTEMS
CTPNV CTP NV
NOVO B NOVO NORDISK A/S
UN0 UNIPER SE
- Roy Külter
- Steven Boumans
- Thomas Zlowodzki
ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 06/11/2024
Notre scénario central s’est concrétisé dans la nuit : Donald Trump remporte la présidentielle américaine, et le choix des électeurs ne devrait pas être contesté. Il pourrait disposer d’une majorité dans les deux assemblées. Les actions américaines en seront les premières bénéficiaires. Sur les actions européennes, les secteurs les plus gagnants seront l’Energie, les Médias, les Métaux, Construction & Materials, Financial Services, Insurance. Sont en revanche plus à risque Utilities, ...
AKE ARKEMA
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
UBSN UBS GROUP AG
PUM PUMA SE
EN BOUYGUES SA
VNA VONOVIA SE
ORSTED ORSTED
FRE FRESENIUS SE & CO. KGAA
NEX NEXANS SA
HEN3 HENKEL AG & CO. KGAA PREF
EDW EDP RENOVAVEIS SA
EVK EVONIK INDUSTRIES AG
INW INFRASTRUTTURE WIRELESS ITALIANE S.P.A.
COLO B COLOPLAST A/S CLASS B
RACE FERRARI NV
AD KONINKLIJKE AHOLD DELHAIZE N.V.
AZN ASTRAZENECA PLC
VOD VODAFONE GROUP PLC
SHL SIEMENS HEALTHINEERS AG
NEOEN NEOEN S.A.
VWS VESTAS WIND SYSTEMS
CTPNV CTP NV
NOVO B NOVO NORDISK A/S
UN0 UNIPER SE
- Baptiste Lebacq
Vestas : Caution still the watchword
>Outperform recommendation, target price of DKK 135 (vs DKK 160) - After the Q3 2024 results release and the conference call, we have revised down our sequence of EPS for 2024-2026 and we reiterate our Underperform rating (despite a performance of -44% YtD), with a target price adjusted to DKK 135). Although the situation is normalising for Power Solutions, we see several risks, particularly with regard to the medium-term EBIT target (group margin expected at 10%), i....
- Douglas Lindahl
Vestas Wind Systems (Buy, TP: DKK215.00) - Service, service and servic...
The Q2 profit warning noted underlying weaknesses in the Service business, and the Q3 report showed continued profitability issues for Service. Thus, we have become even more conservative on the Service business and have cut our group adj. EBIT by c9% on average in 2024–2026e, reduced our target price to DKK215 (235) in line with these cuts, and reiterate our BUY.
- Baptiste Lebacq
Vestas : La prudence reste de mise
>Opinion Sous-performance OC 135 DKK (vs 160 DKK) - Post publication et conférence call, nous ajustons en baisse notre séquence d’EBITDA 2024/26e de 25% en moyenne et réitérons notre recommandation Sous-performance (malgré une performance YtD de -44%) avec un OC abaissé à 135 DKK. Même si la situation est en voie de normalisation du côté de Power Solutions, nous identifions plusieurs risques notamment sur l’objectif d’EBIT à MT (marge groupe attendue à 10%) à savoir ...
- ABGSC Retail Research
- Benjamin Wahlstedt
- Fredrik Ivarsson
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.